Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VPS39 CRISPR/Cas9 KO Plasmid (h): sc-404507
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VPS39 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the VPS39 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VPS39 Antibody (C-5): sc-514762
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VPS39 CRISPR/Cas9 KO Plasmid (h) | sc-404507 | 20 µg | $397.00 |
Overview
VPS39 encodes a core subunit of the HOPS tethering complex that mediates late endosome–lysosome and autophagosome–lysosome fusion, supporting endolysosomal maturation and cargo degradation. Through coordination of Rab GTPase-dependent membrane tethering and SNARE-driven fusion, VPS39 contributes to lysosomal homeostasis, receptor turnover, and macroautophagy flux. Disruption of HOPS components perturbs vesicular trafficking and can drive accumulation of undegraded material, altered signaling from endosomes, and stress responses linked to neurodegenerative and lysosomal storage–like phenotypes. VPS39 is therefore relevant to research on autophagy, endolysosomal dynamics, and disease-associated defects in intracellular trafficking.
VPS39 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the VPS39 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the VPS39 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the VPS39 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish VPS39 protein expression.
This CRISPR knockout system enables efficient generation of VPS39-deficient cell models for investigation of VPS39 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting VPS39 exon(s) critical for VPS39 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple VPS39 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by VPS39 CRISPR/Cas9 KO Plasmid (h) and VPS39 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the VPS39 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by VPS39 HDR Plasmid (h) and VPS39 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by VPS39 homology arms to support homology-directed repair at defined VPS39 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.